Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3389-3395

  Prados, Michael D ^a   Scott, Charles ^a   Curran Jr , Walter J ^a   Nelson, Diana F ^a   Leibel, Steve ^a   Kramer, Simon ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0032729803     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3389     Document Type: Article

References (10)

1. Levin VA, Silva P, Hannigan J, et al: Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic glioma: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324, 1990
2. Levin VA, Prados MD, Wara WM, et al: Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic glioma. Int J Radiat Oncol Biol Phys 32:75-83, 1995
3. Prados MD, Scott CB, Rotman M, et al: Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group (RTOG) trials for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 40:653-659, 1998
4. Nelson DF, Diener-West M, Weinstein AS, et al: A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study. Int J Radiat Oncol Biol Phys 12:1793-1800, 1986
5. Weiner-Wasik M, Scott CB, Nelson DF, et al: Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant glioma: RTOG 83-02. Cancer 77:1535-1543, 1996
6. Scott CB, Curran WJ, Yung WKA, et al: Long term results of RTOG 9006: A randomized trial of hyperfractionated radiotherapy (RT) to 72.0 Gy and carmustine vs standard radiation and carmustine for malignant glioma patients with emphasis on anaplastic astrocytoma patients. Proc Am Soc Clin Oncol 17:401a, 1998 (abstr 1546)
7. Nelson DF, Nelson JS, Davis DR, et al: Survival and prognosis of patients with astrocytoma with atypical or anaplastic features. J Neurooncol 3:99-103, 1985
8. Davis RL: Grading of gliomas, in Fields WS (ed): Primary Brain Tumors: A Review of Histologic Classification. New York, NY, Springer, 1989, pp 150-158
9. Levin VA, Wara WM, Davis RL, et al: Phase III comparison of chemotherapy with BCNU and the combination of procarbazine, CCNU and vincristine administered after radiation therapy with hydroxyurea to patients with malignant gliomas. J Neurosurg 63:218-223, 1985
10. Brada M, Thomas DGT, Bleehen NM, et al: Medical Research Council (MRC) randomised trial of adjuvant chemotherapy in high grade glioma (HGG): BR05. Proc Am Soc Clin Oncol 17:400a, 1998 (abstr 1543)